Fintel reports that on July 24, 2023, Goldman Sachs upgraded their outlook for Amylyx Pharmaceuticals (BATS:AMLX) from Neutral to Buy.
Analyst Price Forecast Suggests 118.63% Upside
As of July 6, 2023, the average one-year price target for Amylyx Pharmaceuticals is 49.30. The forecasts range from a low of 45.45 to a high of $52.50. The average price target represents an increase of 118.63% from its latest reported closing price of 22.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Amylyx Pharmaceuticals is 178MM, an increase of 90.02%. The projected annual non-GAAP EPS is -2.35.
What is the Fund Sentiment?
There are 174 funds or institutions reporting positions in Amylyx Pharmaceuticals. This is an increase of 27 owner(s) or 18.37% in the last quarter. Average portfolio weight of all funds dedicated to AMLX is 0.21%, a decrease of 11.22%. Total shares owned by institutions increased in the last three months by 8.03% to 13,370K shares. The put/call ratio of AMLX is 0.71, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 1,654K shares representing 2.46% ownership of the company. In it’s prior filing, the firm reported owning 1,506K shares, representing an increase of 8.92%. The firm decreased its portfolio allocation in AMLX by 19.50% over the last quarter.
NAESX – Vanguard Small-Cap Index Fund Investor Shares holds 1,388K shares representing 2.07% ownership of the company. In it’s prior filing, the firm reported owning 1,279K shares, representing an increase of 7.86%. The firm decreased its portfolio allocation in AMLX by 17.29% over the last quarter.
IWM – iShares Russell 2000 ETF holds 1,089K shares representing 1.62% ownership of the company. In it’s prior filing, the firm reported owning 1,155K shares, representing a decrease of 5.99%. The firm decreased its portfolio allocation in AMLX by 21.73% over the last quarter.
VISGX – Vanguard Small-Cap Growth Index Fund Investor Shares holds 793K shares representing 1.18% ownership of the company. In it’s prior filing, the firm reported owning 741K shares, representing an increase of 6.51%. The firm decreased its portfolio allocation in AMLX by 21.25% over the last quarter.
KAUAX – Federated Kaufmann Fund Shares holds 775K shares representing 1.15% ownership of the company. No change in the last quarter.
Amylyx Pharmaceuticals Background Information
(This description is provided by the company.)
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
This article originally appeared on Fintel
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
